Cancer Genome Projects have generated a daunting amount of genomic and deep sequencing data for tens of thousands of human tumors. An overarching challenge of this post-genomic era is to identify and recognize the cancer drivers and targets from these daunting amount of big genomic data, especially those that can be therapeutically targeted to improve the clinical outcome. The mission of Dr. Wang’s lab is to apply a multiple disciplinary approach inclusive of integrative bioinformatics, cancer genetics, molecular cancer biology, and translational studies to identify driving genetic aberrations and appropriate cancer targets on the basis of deep sequencing and genomic profiling datasets. His dry lab researches focus on developing innovative and integrative computational technologies and tools to discover causal genetic alternations, viable therapeutic targets, and predictive biomarkers in cancer, as well as understanding the tumorigenic process at systematic level. His wet lab researches focus on experimentally characterizing individual genetic aberrations in breast cancer such as recurrent gene fusions, genomic amplifications, and epimutations, as well as qualifying viable cancer targets and predictive biomarkers for the development of precision therapeutics. For more information, please visit: http://www.cagenome.org/lab.